Global mRNA Therapeutics Market Size To Grow USD 38.15 Billion By 2030 | CAGR of 2.2%

Global mRNA Therapeutics Market worth $38.15 billion by 2030

According to a research report published by Spherical Insights & Consulting, the Global mRNA Therapeutics Market Size to Grow from USD 33.60 Billion in 2021 to USD 38.15 Billion by 2030, at a Compound Annual Growth Rate (CAGR) of 2.2% during the forecast period.

Browse key industry insights spread across 200 pages with 100 market data tables and figures & charts from the report on the "Global mRNA Therapeutics Market Size, Share, and COVID-19 Impact Analysis, By Application (Infectious Diseases, Oncology), By Type (Prophylactic Vaccines, Therapeutic Drugs), By End-use (Hospitals and Clinics, Research Organizations, Others), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030" Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/mrna-therapeutics-market

The building block of protein synthesis in cells, messenger ribonucleic acid, is a single protein-coding gene (mRNA). mRNA vaccines and RNA interference (RNAi) treatments, which are produced in labs using mammalian cells, combine the desired immunological properties. Some of the frequently utilised vaccination and therapy kinds include self-amplifying, non-replicating, in vivo self-replicating, and in vitro dendritic cell non-replicating mRNA. They are administered intravenously to turn on the immune system's sensors for viruses and trigger the creation of viral antigen proteins by cells. The consequence is an improvement in the body's B- and T-cell responses, which aids in boosting immunity.

Over the past ten years, there has been a marked rise in the prevalence of infectious and chronic diseases worldwide. Putting personal hygiene and safety precautions aside, the prevalence of communicable and chronic diseases is rising. Food and nutrition are the primary factors that determine whether or not such diseases will occur, yet falling nutrient content in food is the cause of rising disease prevalence. Cancers, diabetes, neurological conditions, osteoporosis, and cardiovascular issues are among the most prevalent chronic diseases. According to a UN study, there would be more than 11 million deaths worldwide from cancel in 2021.

The Market is expanding as a result of an increase in both chronic illnesses including cancer, heart disease, CKD, pulmonary, and others as well as rare conditions like propionic metabolic acidosis, methylmalonic acidaemia, glycogen sickness, immunological disorders, metabolism, and phenylketonuria. For instance, according to the Globo can, millions of cancer-related fatalities will occur Worldwide in 2020.

The rising incidence of chronic and infectious diseases is expected to raise demand for mRNA vaccines and RNAi therapies globally over the predicted period. The sensitivity of the therapy, targeted specialisation, and improved awareness of immunisation are further aspects that significantly contribute to the market's expansion. Yet, the expansion of the market will be hampered by the possibility of failing in market studies when quantifying mRNA. As part of a joint venture with Axcelead, Inc., US mRNA therapeutic developer Arcturus Therapeutics founded a Japanese company in Chiba Prefecture in 2021. Currently, the company is constructing a production facility in Minami soma City, Fukushima Prefecture. Such expenditures are likely to support market expansion in the years to come.

COVID 19 Impact

After COVID 19 trials, which have boosted the industry, the year 2021 has seen the second-highest quantity of mRNA vaccination research and development activities with cancer patients. Positive market effects from the COVID 19 pandemic have led to an increase in demand for mRNA therapies worldwide. This has led to a rise in the number of COVID 19 patients around the world and significant outside funding for the creation of COVID 19 vaccines. In addition, because mRNA immunisations offer a powerful defence against many COVID 19 health problems, the demand for these vaccines has skyrocketed throughout the world.

The prophylactic vaccines segment accounted the largest market share over the forecast period.

On the basis of type, the Global mRNA Therapeutics Market Size is segmented into prophylactic vccines, therapeutic vaccines, and therapeutic drugs. Among these, the prophylactic vaccines segment is dominating the market and is going to continue its dominance over the forecast period. The prophylactic vaccinations are the outcome of current research and development efforts, with more than 50% of mRNA firms having at least one preventive vaccine in development, according to the data provided by Nature's viewpoint. The category growth is also aided by other vaccines for illnesses including influenza and respiratory syncytial virus, but COVID-19 products presently generate the largest majority of profits from preventative vaccinations. The expansion of the sector has been impacted by increasing mergers and acquisitions as well as increased R&D activities by biopharmaceutical companies to improve various preventative vaccination types. A portfolio of investments for the research and marketing of preventative vaccines for infectious diseases, for instance, has been declared complete by Pfizer and Valneva for completion in 2022.

The infectious disease segment is dominating the market with the largest revenue share over the forecast period.

On the basis of application, the global mRNA Therapeutics Market is segmented into Infectious Diseases, Oncology. Among these, the infectious disease segment is dominating the market with the largest revenue share of 99.8% over the forecast period. Throughout the course of the projection period, the market will be driven by an increase in the use of mRNA vaccines, the COVID 19 pandemic, and an increase in the number of candidates entering clinical trials for various communicable illnesses. On the other hand, it is projected that the oncology section will grow significantly during the forecast period. Lung, rectum, colon, stomach, liver, and breast cancers, as previously indicated, are contributing to an increase in fatalities worldwide. Thus, rising chronic disease rates would boost demand for mRNA vaccination therapies, which are propelling the market throughout the projection period. Additionally, the shortage of precision cancer therapy medications is pressuring the government and major market participants to engage in R&D projects that would promote segmental growth.

The hospitals and clinics segment accounted the largest revenue share of more than 61.2% over the forecast period.

On the basis of end use, the global mRNA Therapeutics Market is segmented into hospitals and clinics, research organizations, and others. Among these, the hospitals and clinics segment accounted the largest revenue share of over 61.2% over the forecast period. Future personal medications will benefit from the rising use of vaccines and treatments for a variety of chronic illnesses. In addition, the market is being driven by the growing number of people visiting hospitals and clinics. Additionally, it is projected that the market will be driven by the rising number of patients with infectious diseases, influenza, cancer, and respiratory issues. For instance, according to the NCBI research from 2019 WHO predicted that up to 500,000 people die from influenza each year and that around one billion people are unwell, which is why hospitals and doctors' offices are expanding.

North America dominates the market with the largest market share over the forecast period.

With a market share of more than 35.6% during the forecast period, North America is the industry leader. The key driver of this region's expansion is the availability of research funds. The extension of federal programmes for RNA-based drugs as well as an increase in the number of clinical trials will also contribute to this region's expansion. For instance, Graham has received considerable backing from the National Institutes of Health (NIH) and the Defence Department for his basic research, which has aided in the quick creation of COVID 19 vaccines.

Due to the potential for gene silencing in these therapies and the market for mRNA-based therapeutics, the Asia-Pacific area is growing at a promising CAGR. Nonetheless, the market is still in its early stages in developing countries like India, and it has experienced profitable growth during the course of the analysis period. The Asia-Pacific market will continue to grow as a result of factors such the target specificity and selectivity of RNAi treatments, more focused product focus compared to platform technologies, and virtual drug development models that allow companies to reduce research costs.

Major vendors in the Global mRNA Market include Alnylam Pharmaceuticals, BioNTech AG, CureVac AG, eTheRNA Immunotherapy, Ethris GmbH, In-Cell-Art, Moderna Therapeutics, Sanga Mon therapeutic Inc., Sanofi AG, SCM Life science Co., Ltd, Sarepta Therapeutics, Arcturus Therapeutics, Ionis pharmaceuticals Inc., Nutcracker Therapeutics, TIBA Biotech.

Key Market Developments

• In November 2022, Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine is approved for use by Health Canada as a booster dose in people 18 years of age and older. Similar bivalent booster doses from Moderna (50 mcg) and Pfizer-BioNTech (30 mcg) with Omicron BA.1 or BA.4/5 variants were already approved by Health Canada in September and October of 2022, respectively.

• In October 2022, Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine is approved for use by Health Canada as a booster dose in people 18 years of age and older. Similar bivalent booster doses from Moderna (50 mcg) and Pfizer-BioNTech (30 mcg) with Omicron BA.1 or BA.4/5 variants were already approved by Health Canada in September and October of 2022, respectively.

List of Key Market Players

• Alnylam Pharmaceuticals
• BioNTech AG
• CureVac AG
• eTheRNA Immunotherapy
• Ethris GmbH
• In-Cell-Art
• Moderna Therapeutics
• Sangamon therapeutic Inc.
• Sanofi AG
• SCM Lifescience Co., Ltd
• Sarepta Therapeutics
• Arcturus Therapeutics
• Ionis pharmaceuticals Inc.
• Nutcracker Therapeutics
• TIBA Biotech

Market Segment

This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global mRNA Therapeutics market based on the below-mentioned segments:

mRNA Therapeutics Market, Application Analysis

• Infectious Diseases
• Oncology

mRNA Therapeutics Market, Type Analysis

• Prophylactic vaccines
• Therapeutic vaccines
• Therapeutic drugs

mRNA Therapeutics Market, End User Analysis

• Hospitals and clinics
• Research organizations
• Others

mRNA Therapeutics Market, Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

About the Spherical Insights & Consulting

Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.

Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements. 

CONTACT US:

For More Information on Your Target Market, Please Contact Us Below:    

Phone: +1 303 800 4326 (the U.S.)

Phone: +91 90289 24100 (APAC)

Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com

Contact Us: https://www.sphericalinsights.com/contact-us

Follow Us: LinkedIn | Facebook | Twitter